A phase I study of alpelisib + trastuzumab + LJM716 for PIK3CA-mutated HER2+ metastatic breast cancer June 14, 2021
Patient-reported outcomes in patients with PIK3CA-mutated HR+, HER 2–negative advanced breast cancer from SOLAR-1 March 29, 2021